250 related articles for article (PubMed ID: 26521944)
21. The dietary flavone luteolin epigenetically activates the Nrf2 pathway and blocks cell transformation in human colorectal cancer HCT116 cells.
Zuo Q; Wu R; Xiao X; Yang C; Yang Y; Wang C; Lin L; Kong AN
J Cell Biochem; 2018 Nov; 119(11):9573-9582. PubMed ID: 30129150
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic markers in human gliomas: prospects for therapeutic intervention.
Hesson LB; Krex D; Latif F
Expert Rev Neurother; 2008 Oct; 8(10):1475-96. PubMed ID: 18928342
[TBL] [Abstract][Full Text] [Related]
23. An update on the epigenetics of glioblastomas.
Ferreira WA; Pinheiro Ddo R; Costa Junior CA; Rodrigues-Antunes S; Araújo MD; Leão Barros MB; Teixeira AC; Faro TA; Burbano RR; Oliveira EH; Harada ML; Borges Bdo N
Epigenomics; 2016 Sep; 8(9):1289-305. PubMed ID: 27585647
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
25. xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization.
Savaskan NE; Eyüpoglu IY
Ann Anat; 2010 Sep; 192(5):309-13. PubMed ID: 20801625
[TBL] [Abstract][Full Text] [Related]
26. The epigenetics of brain tumors and its modulation during radiation: A review.
Raviraj R; Nagaraja SS; Selvakumar I; Mohan S; Nagarajan D
Life Sci; 2020 Sep; 256():117974. PubMed ID: 32553924
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
28. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
30. Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis.
Kim HS; Shen Q; Nam SW
J Korean Med Sci; 2015 Oct; 30(10):1375-80. PubMed ID: 26425032
[TBL] [Abstract][Full Text] [Related]
31. NOS Expression and NO Function in Glioma and Implications for Patient Therapies.
Tran AN; Boyd NH; Walker K; Hjelmeland AB
Antioxid Redox Signal; 2017 Jun; 26(17):986-999. PubMed ID: 27411305
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic therapies reach main street.
Bates SE
Clin Cancer Res; 2009 Jun; 15(12):3917. PubMed ID: 19528089
[No Abstract] [Full Text] [Related]
33. DNMTs as potential therapeutic targets in high-risk pediatric embryonal brain tumors.
Sin-Chan P; Huang A
Expert Opin Ther Targets; 2014 Oct; 18(10):1103-7. PubMed ID: 25142793
[TBL] [Abstract][Full Text] [Related]
34. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation.
MacDonald JL; Roskams AJ
Prog Neurobiol; 2009 Jul; 88(3):170-83. PubMed ID: 19554713
[TBL] [Abstract][Full Text] [Related]
37. Epigenetics in human melanoma.
Howell PM; Liu S; Ren S; Behlen C; Fodstad O; Riker AI
Cancer Control; 2009 Jul; 16(3):200-18. PubMed ID: 19556960
[TBL] [Abstract][Full Text] [Related]
38. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
39. Linking epigenetics to lipid metabolism: focus on histone deacetylases.
Ferrari A; Fiorino E; Giudici M; Gilardi F; Galmozzi A; Mitro N; Cermenati G; Godio C; Caruso D; De Fabiani E; Crestani M
Mol Membr Biol; 2012 Nov; 29(7):257-66. PubMed ID: 23095054
[TBL] [Abstract][Full Text] [Related]
40. Advances on Epigenetic Drugs for Pediatric Brain Tumors.
Skouras P; Markouli M; Strepkos D; Piperi C
Curr Neuropharmacol; 2023; 21(7):1519-1535. PubMed ID: 36154607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
